Delving into the Latest Updates on Recombinant human nerve growth factor(Jiangsu Zhongxin Medicine Co Ltd) with Synapse

Overview

Basic Info

Drug Type

Growth factors

Synonyms

+ [1]

Target

p75NTR

Action

agonists, stimulants

Mechanism

p75NTR agonists(Low affinity neurotrophin receptor p75NTR agonists), Neurons stimulants

Therapeutic Areas

Nervous System DiseasesEye DiseasesOther Diseases

Active Indication

Glaucoma, Open-AngleOptic Nerve InjuriesNeurotrophic keratitis

Inactive Indication-

Originator Organization

Jiangsu Zhongxin Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Zhongxin Pharmaceutical Co., Ltd.

Inactive Organization

Dompé Pharmaceutici Spa

Drug Highest PhasePhase 2

First Approval Date-

RegulationSpecial Review Project (China)

Login to view timeline

主要目的：评价在健康受试者中单次、多次局部给予ZX1305滴眼液后的全身系统安全性、耐受性。次要目的：1.评价在健康受试者中单次、多次局部给予ZX1305滴眼液后全身系统的药代动力学特征；2.评价在健康受试者中单次、多次局部给予ZX1305滴眼液后全身系统免疫原性。

[Translation]

Primary objective: To evaluate the systemic safety and tolerability of single and multiple topical administration of ZX1305 eye drops in healthy subjects. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of the systemic system after single and multiple topical administration of ZX1305 eye drops in healthy subjects; 2. To evaluate the systemic immunogenicity of ZX1305 eye drops in healthy subjects after single and multiple topical administration.

Start Date27 Aug 2024

Sponsor / Collaborator

Jiangsu Zhongxin Pharmaceutical Co., Ltd.

CTR20230387

/ RecruitingPhase 2

重组人神经生长因子（ZX1305）注射液治疗视神经损伤有效性、安全性和免疫原性的Ⅱ 期临床研究

[Translation] Phase II clinical study on the efficacy, safety and immunogenicity of recombinant human nerve growth factor (ZX1305) injection in the treatment of optic nerve damage

主要研究目的：探索肌肉注射不同剂量的重组人神经生长因子（ZX1305）注射液治疗视神经损伤的有效性，为Ⅲ期临床试验设计提供依据。次要研究目的：探索肌肉注射不同剂量的重组人神经生长因子（ZX1305）注射液治疗视神经损伤的安全性和免疫原性。

[Translation]

The main purpose of the study is to explore the effectiveness of intramuscular injection of different doses of recombinant human nerve growth factor (ZX1305) injection in the treatment of optic nerve damage, and to provide a basis for the design of Phase III clinical trials. Secondary purpose of the study is to explore the safety and immunogenicity of intramuscular injection of different doses of recombinant human nerve growth factor (ZX1305) injection in the treatment of optic nerve damage.

Start Date26 Jun 2023

Sponsor / Collaborator

Jiangsu Zhongxin Pharmaceutical Co., Ltd.

CTR20230957

/ RecruitingPhase 2

重组人神经生长因子（ZX1305）注射液治疗开角型青光眼导致的视神经损伤有效性、安全性和免疫原性的II期临床研究

[Translation] Phase II clinical study on the efficacy, safety and immunogenicity of recombinant human nerve growth factor (ZX1305) injection in the treatment of optic nerve damage caused by open-angle glaucoma

主要研究目的：探索肌肉注射重组人神经生长因子（ZX1305）注射液治疗开角型青光眼导致的视神经损伤的有效性，为后期临床试验设计提供依据。次要研究目的：探索肌肉注射重组人神经生长因子（ZX1305）注射液治疗开角型青光眼导致的视神经损伤的安全性和免疫原性。

[Translation]

The main purpose of the study is to explore the effectiveness of intramuscular injection of recombinant human nerve growth factor (ZX1305) injection in the treatment of optic nerve damage caused by open-angle glaucoma, and to provide a basis for the design of later clinical trials. Secondary purpose of the study is to explore the safety and immunogenicity of intramuscular injection of recombinant human nerve growth factor (ZX1305) injection in the treatment of optic nerve damage caused by open-angle glaucoma.

Start Date10 May 2023

Sponsor / Collaborator

Jiangsu Zhongxin Pharmaceutical Co., Ltd.

100 Clinical Results associated with Recombinant human nerve growth factor(Jiangsu Zhongxin Medicine Co Ltd)

Login to view more data

100 Translational Medicine associated with Recombinant human nerve growth factor(Jiangsu Zhongxin Medicine Co Ltd)

Login to view more data

100 Patents (Medical) associated with Recombinant human nerve growth factor(Jiangsu Zhongxin Medicine Co Ltd)

Login to view more data

4

Literatures (Medical) associated with Recombinant human nerve growth factor(Jiangsu Zhongxin Medicine Co Ltd)

01 Jan 2001·Journal of Molecular BiologyQ2 · BIOLOGY

Pro-sequence assisted folding and disulfide bond formation of human nerve growth factor††Dedicated to Rita Levi-Montalcini.22Edited by R. Huber

Q2 · BIOLOGY

Article

Author: Floriana Vinci ; Margherita Ruoppolo ; Hauke Lilie ; Anke Rattenholl ; Angela Flagiello ; Maria Monti ; Rainer Rudolph ; Elisabeth Schwarz ; Gennaro Marino

Nerve growth factor (NGF) is a member of the neurotrophin family. These growth factors support neuronal survival and differentiation. Neurotrophins are synthesized as pre-pro-proteins. Whereas the pre-sequences mediate secretion, the function of the pro-peptides is largely unknown. To test the role of the pro-sequence as a folding enhancer, recombinant human pro-NGF (rh-pro-NGF) was produced in Escherichia coli. The oxidative refolding of rh-pro-NGF and rh-NGF was studied using electrospray mass spectrometry (ESIMS) time-course analysis. This analysis permitted both the identification and quantification of intermediates present during the process. The disulfide bonds formed at different times of the refolding processes were characterized by proteolytic digestion followed by matrix assisted laser desorption ionization mass spectrometry (MALDIMS) analysis. Folding yields and kinetics of rh-pro-NGF were significantly enhanced when compared to the in vitro refolding of mature rh-NGF. These results suggest that the pro-sequence of NGF promotes folding of the mature part.

01 Apr 1993·European Journal of PharmacologyQ3 · MEDICINE

Recombinant human type II phospholipase A2 lacks edema producing activity in rat

Q3 · MEDICINE

Article

Author: Anderson, Celia M. ; Meyers, Kenneth P. ; Morgan, Douglas W.

The rat paw edema-inducing, acute inflammatory activity of four snake venom phospholipase A2S (PLA2) (Naja naja, Naja mocambique mocambique, Crotalus atrox and recombinant Naja naja naja) and of recombinant human type II PLA2 (rh-PLA2) found in rheumatoid synovial fluid, were compared after a bolus subplantar injection. The snake venom-derived PLA2s, including the recombinant Naja naja naja, were potent inducers of paw edema. On the other hand, when given in similar amounts (protein and/or enzymatic activity), the rh-PLA2 did not produce paw edema. Furthermore, the addition of Naja naja PLA2, blood plasma from rats with adjuvant arthritis or the E. coli-based enzymatic incubation mixture used to measure PLA2 activity to the injection mixture containing rh-PLA2, did not result in paw edema-inducing activity. These results suggest that the lack of paw edema-inducing activity of rh-PLA2 may be due to significant structural differences between snake venom PLA2s and human PLA2 which allow snake venom PLA2s, but not the human group II PLA2, to express inflammatory activity as measured by paw edema in rat induced by a bolus injection.

01 Apr 1988·American Journal of Physiology-Renal Physiology

Vasoconstrictor-induced changes in renal blood flow: role of prostaglandins and histamine

Article

Author: Banks, R. O.

The role of histamine (H) and prostaglandins (PGs) in the renal vasoconstriction prompted by a 10-min intrarenal infusion of norepinephrine (NE, 0.2 micrograms), antidiuretic hormone (ADH, 10 mU), or angiotensin II (ANG II, 0.05 micrograms) was evaluated in anesthetized dogs (amounts are per min per kg). Renal blood flow (RBF, flow probe) decreased four- to fivefold during the 1st min of infusion with each agonist but then gradually returned toward base line. This “escape” was greatest with ADH, less with NE, and small with ANG II. There was a postinfusion reactive hyperemia (RH) only after NE; NE-RH was 4.26 +/- 0.75 (SE) ml/g. Meclofenamate (MFA) reduced NE-RH to 60 +/- 11% of control and decreased NE escape. The H1-receptor antagonist, chlorpheniramine (CP), decreased NE-RH to 24 +/- 5% of control and reduced NE escape. MFA slowed, but did not block, ADH escape and had little effect on ANG II escape. CP did not affect ADH or ANG II escape. The histidine decarboxylase inhibitor, p-toluenesulfonohydrazine, did not affect NE escape but decreased NE-RH to 22 +/- 6% of control. Bolus injections of ADH during a constant infusion of the hormone were not vasoactive, indicating a tachyphylaxis-like phenomenon; this was not found with ANG II or NE. Finally, the excretion of histamine-like material increased from a control value of 0.69 +/- 0.08 to 1.28 +/- 0.28 micrograms/min during NE-RH. These results indicate that NE releases histamine and PGs from the kidney and that PGs account, primarily, for NE escape, whereas histamine accounts, primarily, for NE-RH.

100 Deals associated with Recombinant human nerve growth factor(Jiangsu Zhongxin Medicine Co Ltd)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Phase 2	China	Jiangsu Zhongxin Pharmaceutical Co., Ltd.	10 May 2023
Optic Nerve Injuries	Phase 2	China	Jiangsu Zhongxin Pharmaceutical Co., Ltd.	10 May 2023
Neurotrophic keratitis	Phase 1	China	Jiangsu Zhongxin Pharmaceutical Co., Ltd.	27 Aug 2024
Glaucoma	Preclinical	United States	Dompé Pharmaceutici Spa	01 Dec 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data